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Abstract
Background: High dosage of intravenous immunoglobulin (IVIG) has been observed as a possible activator of HIV
gene expression in latently infected resting CD4
+ T-cells, leading to a substantial decrease in both the reservoir and
the residual plasma viremia when added to effective ART. IVIG treatment has also been reported to expand T
regulatory cells (Tregs). The aim of this study was to evaluate possible long-term effect of IVIG treatment on
residual viremia and T-lymphocyte activation.
Methods: Nine HIV-infected subjects on effective ART included in a previously reported study on IVIG treatment
were evaluated 48-104 weeks after therapy. In addition, 14 HIV-infected controls on suppressive ART were included.
HIV-1 RNA was analyzed in cell-free plasma by using an ultrasensitive PCR-method with a detection limit of 2
copies/mL. T-lymphocyte activation markers and serum interleukins were measured.
Results: Plasma residual viremia rebounded to pre-treatment levels, 48-104 weeks after the initial decrease that
was observed following treatment with high-dosage IVIG. No long-term effect was observed regarding T-
lymphocyte activation markers, T-regulatory cells or serum interleukins. In a post-hoc analysis, a correlation
between plasma HIV-1-RNA and CD4
+ T-cell count was found in both IVIG-treated patients and controls.
Conclusions: These results indicate that the decrease in the latent HIV-1 pool observed during IVIG treatment is
transient. Although not our primary objective, we found a correlation between HIV-1 RNA and CD4
+ T-cell count
suggesting the possibility that patients with a higher CD4
+ T-cell count might harbor a larger residual pool of
latently infected CD4
+ T-cells.
Background
The latency of HIV-1 in resting CD4
+ T-lymphocytes
constitutes a major obstacle for the eradication of virus
in patients on otherwise effective antiretroviral therapy
(ART) [1]
High dosage of intravenous immunoglobulin (IVIG) has
been proposed as a possible activator of HIV gene expres-
sion in latently infected resting CD4
+ T-cells. In a previous
study, patients on ART were given 30 g immunoglobulin
intravenously per day for 5 consequent days (0,4 g/kg).
When IVIG was added to effective ART, a substantial
decrease in residual plasma viremia and in the virus reser-
voir was observed in a majority of subjects [2]. The latent
HIV-1 pool in resting CD4
+ T-cells decreased with
in median 68% after addition of IVIG. The reservoir
decreased in five, whereas no decrease was found in two
subjects with detectable virus. Plasma HIV-1 RNA ≥ 2
copies/mL was detected in five of seven subjects at base-
line, but in only one at follow-up after 8-12 weeks. The
decrease in the latent HIV-1 pool and the residual plasma
viremia was preceded by an initial transitory low-level
increase in plasma HIV-1 RNA during IVIG treatment
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latent reservoir [2,3]. Viral clones from plasma clustered
together with virus from latently infected memory T-cells
as measured by single genome sequencing (SGS) of the
gag region. Furthermore, the magnitude of the increase in
HIV-1 RNA in plasma correlated with the size of the
latent HIV-1 pool. IVIG also resulted in a consistent
increase of CD25
+CD127
- regulatory T-cells (Tregs) from
median 1.4 (IQR: 0.96-2.2)% to 2.3 (1.3-3.3)%, in all sub-
jects after IVIG treatment, p = 0.0036 [2]. The aim of this
follow-up study was to investigate if the observed decrease
of residual viremia and increase of Tregs was transient or
maintained over time. In addition we aimed to analyze the
relationship between low-level residual viremia and
immune activation markers during effective ART.
Materials and methods
Patients
The nine patients that were included in the previously
presented IVIG-study [2] were sampled again, 48-104
weeks after treatment with IVIG. They had all been on
suppressive ART ≥2 years and had plasma HIV-1 RNA
levels < 50 copies/mL ≥1,5 years before the IVIG ther-
apy was given in accordance with the study protocol.
HIV-1 RNA remained < 50 copies/mL in all subjects
between the time of the previous study and new follow-
up sampling. In addition, 14 HIV-infected subjects on
suppressive ART and fulfilling the same inclusion cri-
teria as stated above were included as controls. The
control group was not part of the original study. Patient
characteristics are shown in Table 1. All subjects pro-
vided written informed consent, and the study was
approved by the Research Ethics Committee at the Uni-
versity of Gothenburg.
Methods
Quantification of HIV-1 RNA in plasma
HIV-1 was quantified in cell-free plasma by a previously
described modified version of the Roche Amplicor Moni-
tor Test (Version 1.5, Roche Diagnostic Systems, Hoff-
man-La Roche, Basel, Switzerland) with a lower dynamic
detection limit of 2 copies/mL [4]. The method allows
detection by signal below 2 copies but cannot differentiate
an exact number of copies below this limit. In graphs,
samples with positive HIV-1 RNA PCR signal below 2
copies/mL were denoted as 1,5 copies/mL whereas sam-
ples with negative HIV-1 RNA PCR signal were denoted
as 1 copy/mL. All plasma HIV-1 RNA samples with values
below the quantitative detection limit but with a PCR sig-
nal were counted as < 2 copies/mL in calculations.
Cytokine analysis
Plasma samples from all patients were analyzed for the
presence of IL-2 and IL-7 cytokines on a Luminex
100™ System (Luminex Corp, Austin, TX, USA). The
procedure is described in a protocol supplied with the
IL-2 and IL-7 Human Singleplex Bead Kits (Invitrogen).
Abs from the two kits were combined, and undiluted
plasma samples were thoroughly mixed, centrifuged, and
filtered prior to analysis.
T-cell assays, flow cytometry, and mAbs
Peripheral blood CD4
+ and CD8
+ T-cell counts were
measured by direct immunofluorescence in a flow cyt-
ometer. Flow cytometry was used for phenotypic analysis
of lymphocytes and measurement of T-lymphocyte acti-
vation markers CD38 and HLA-DR. For each sample, 7 ×
10
5 freshly isolated PBMC were stained for surface mar-
kers in a 96-well v-bottomed plate on ice for 30 min,
washed three times in PBS with 1% FCS, before permea-
bilization with Foxp3 staining buffer (eBiosciences) at
4°C for 30 min. Cells were then washed with Permeabili-
zation buffer and stained for intranuclear Foxp3 for
30 min, washed three times, and resuspended in Permea-
bilization buffer. For intracellular staining of cytokines,
cells were stained for surface markers before permeabili-
zation with Perm/Fix solution (BD Biosciences) at 4°C
for 20 min. Cells were then washed with Perm/Wash
solution and stained for intracellular IFNg, MIP-1b,I L - 2 ,
and TNFa for 30 min, washed three times, and resus-
pended in CellFix solution. Multicolor flow cytometry
data was acquired on a CyAn ADP instrument (Dako)
[5]. Data were analyzed using FlowJo software (Tree Star,
Ashland, OR, USA). The HIV-Gag p55 peptide pool (JPT
Peptide Technologies, Berlin, Germany) was used to
study the HIV-1-specific responses, and a CMV, EBV,
and Flu (CEF) control peptide pool, as well as Staphylo-
coccal Enterotoxin B (SEB) (SIGMA-Aldrich Logistic
G m b H ,S c h n e l l d o r f ,G e r m a n y ), were added as positive
controls. The PBMCs were plated at a concentration of
1×1 0
6 cells/well, along with peptides at a final concen-
tration of 2 μg/mL per peptide in the pool, and incubated
at 37°C for 12 hrs. As a negative control, cells were incu-
bated with medium only to determine the background
responses for each patient. The following mAbs were
used: anti-CD3 PE-Cy7, anti-CD8 PerCP, anti-CD25 PE,
anti-CD38 FITC PE-Cy7, anti-CD127 Alexa647, anti-
HLA-DR APC-Cy7, anti-IFNg FITC, anti-MIP-1b PE,
and anti-IL-2 APC, all from BD Biosciences (San Diego,
CA, USA). TNFa Pacific Blue from eBioscience, Anti-
CD3 Pacific Blue from Dako (Copenhagen, Denmark),
anti-Foxp3 A488 from Biolegend, anti-CD4 Qdot 605
and Aqua Live/Dead cell exclusion marker from
Invitrogen.
Statistics
Statistical analyses were performed by using Graphpad
Prism 5.0 for Mac OS X. The Mann-Whitney U-test
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groups, Wilcoxon Signed Rank test for pair wise com-
parisons, and Spearman’s Rank Correlation Coefficient
for evaluations of correlations. The One-way ANOVA-
test was used for calculations of repeated measures.
Results
Plasma HIV-1 RNA
Plasma residual viremia rebounded to pre-treatment
levels at patient follow-up, 48-104 weeks after the initial
decrease observed at 8-12 weeks after treatment with
high-dosage IVIG. At follow-up, six out of nine patients
(subjects 1-3 and 7-9) had detectable levels of plasma
HIV-RNA compared to one patient (subject 7), 8-12
weeks after IVIG treatment. Three of the subjects (sub-
jects 4-6) had undetectable levels of plasma HIV-1 RNA
at follow-up and another two (subjects 2 and 3) had
detectable plasma HIV-1 RNA below 2 copies/mL,
Figure 1. There was no significant difference in plasma
HIV-1 RNA between IVIG-treated subjects (median < 2
copies/mL, IQR < 2-12 copies/mL) and controls (med-
ian < 2 copies/mL, IQR < 2-7.2 copies/mL) at follow-up,
Figure 1.
T-cell analyses
We did not detect any significant difference in Treg
(CD4
+CD25
+CD127
-FoxP3
+) proportion of peripheral
blood CD4
+ T-cells between IVIG-treated patients
(median 0.86%, IQR 0.60-1.21%) and controls (median
0.91%, IQR 0.79-1.33%).
Different antibodies were used in the previous study
to identify Tregs making direct comparisons of results
from the period during IVIG treatment and follow-up
impossible.
No change in peripheral CD4
+ T-cell count was detected
from baseline to follow-up or during the IVIG-treatment.
Table 1 Patient characteristics
Patient Number*
(Age, sex)
ART regimen Duration (months) CD4
+ T-cell count (cells/μL)
Total time
under treatment
Time with HIV-1
RNA < 50 copies/mL
Time in treatment after IVIG
administration
Current Nadir
1 (65,M) ABC+3TC+EFV 103 96.1 24.3 470 180
2 (53,M) TDF+FTC+EFV 147.6 105.3 21.6 790 200
3 (35,M) ABC+ZDV+3TC
+LPV/r
76.6 73.6 20.5 180 20
4 (36,F) ABC+3TC+ATV/r 76 71 21.5 430 50
5 (58,M) 3TC+ABC+LPV/r 145.6 84.3 11.7 150 40
6 (36,M) ZDV+3TC+EFV 132.7 48.3 12.4 240 120
7 (43,M) TDF+FTC+LPV/r 99 32 10.6 550 40
8 (45,M) 3TC+ABC+NVP 95.4 87.2 12.1 310 30
9 (43,M) TDF+FTC+ATV/r 92.6 79.3 12.3 640 90
Median 99 79.3 12.4 430** 50
C1 (38,F) 3TC+ABC+ATV/r 56.7 55.9 910 176
C2 (45,M) ZDV+3TC+SQV/r 88.4 75.1 730 230
C3 (26,F) 3TC+ABC+EFV 47 46.2 470 240
C4 (47,F) TDF+FTC+LPV/r 84.6 80 1000 20
C5 (44,F) ETV+ATV/r+RAL 94.7 80.4 530 42
C6 (42,M) ZDV+FTC+EFV 55.8 50.3 430 80
C7 (39,F) 3TC+ABC+ATV/r 104 110.2 480 17
C8 (61,M) TDF+FTC+EFV 134 78.5 530 340
C9 (42,F) 3TC+ABC+LPV/r 132 128.6 510 40
C10 (56,M) ZDV+3TC+ABC 153.4 140.4 750 45
C11 (36,F) 3TC+ABC+LPV/r 100.4 93.1 700 200
C12 (43,M) 3TC+ABC+LPV/r 32.1 24.3 550 190
C13 (46,F) TDF+FTC+EFV 83.6 71.9 330 40
C14 (37,F) ZDV+3TC+LPV/r 62.3 58.3 720 140
Median 86.5 76.8 540** 110
* Controls are denoted C1-C14
** CD4
+ T-cell count differed between groups (p = 0.05)
ABC, abakavir; ATV/r, atazanavir/ritonavir; EFV, efavirenz; ETV, entecavir; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; NVP, nevirapine; RAL, raltegravir; SQV/r,
saquinavir/ritonavir; TDF, tenofovir; ZDV, zidovudine; 3TC, lamivudine;
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cells/μL, IQR 210-595) compared to controls (median 540
cells/μL, IQR 478-755) was observed at follow-up (p =
0.05). The CD4
+ T-cell nadir was also lower in patients
treated with IVIG (median 50 cells/μL, IQR 35-150) than
in controls (median of 110 cells/μL, IQR 40-208), however,
t h ed i f f e r e n c ew a sn o ts t a t i stically significant. CD4
+ T-
lymphocyte activation as measured by expression of CD38
was lower for IVIG-treated patients at follow-up compared
to controls (44.5% IQR 37.7-58.6 for IVIG treated, 58.5%
IQR 47.9-70.2 for controls, p = 0.04). CD38 expression of
CD8
+ T-lymphocytes was also lower for IVIG-treated
patients (10.1% IQR 7.2-17.2% for IVIG treated, 15.2%
IQR 12.5-23.8% for controls, p = 0.07). However, CD38-
expression on CD4
+and CD8
+ T-cells was stable during
IVIG-treatment with no difference compared to baseline
levels within the IVIG-treated group. Therefore, results
are probably a consequence of differences between groups
irrespective of IVIG treatment. HLA-DR expression of
CD4
+ or CD8
+ T-lymphocytes did not differ between the
groups. No effect was observed on HIV-specific CD8
+ T-
cell responses against Gag peptide pools when IVIG trea-
ted patients were compared with controls.
Correlations with plasma HIV-1 RNA
The level of residual plasma viremia in both groups cor-
related with CD4
+ T-cell count (r = 0.46, p = 0.03),
Figure 2. Nadir CD4
+ did not correlate to levels of
plasma HIV RNA. A correlation was seen between
plasma HIV-1 RNA levels and the total number of
Tregs in IVIG-treated patients (r = 0.51, p = 0.02).
However, when analyzing the proportion of Tregs of
lymphocytes in relation to plasma viral load, no signifi-
cant correlation was found. No significant correlations
were found between plasma HIV-1 RNA and expression
of CD38 and HLA-DR% of CD4
+ or CD8
+ T-lympho-
cytes. Neither were any correlations found to levels of
IL-2 and IL-7 or HIV-specific CD8
+ T-cell responses
against Gag peptide pools. No statistically significant
correlation was found when comparing plasma HIV-1
RNA before antiretroviral treatment initiation to levels
of residual viremia (r = 0.35, p = 0.11).
Discussion
Residual viremia in HIV-infected patients on ART is
thought to originate mainly from a small pool of latently
infected resting memory CD4
+ T-cells [1,6,7]. As
demonstrated in a recent study, viral load stabilizes
within one year of treatment. However, residual low-
level viremia remains measurable in a majority of
patients even after as long as 7 years on suppressive
therapy. The decay rate of residual viremia has been
shown to be quite slow, with an estimated half-life of
9-15 months or longer [8]. Furthermore it has been
established in several studies that the pool of latently
infected cells is not affected by treatment intensification
[9,10]. It is evident that the latent reservoir cannot be
eliminated by the standard antiviral therapy currently
available and this calls for alternative methods in manip-
ulating the pool of latently infected cells. We have
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Figure 1 The effect of intravenous immunoglobulin (IVIG) on
plasma HIV-1 RNA. Rebound of plasma HIV-1 RNA to pre-
treatment levels at follow-up after initial decrease 8-12 weeks after
treatment with IVIG. At follow-up six out of nine patients had
detectable levels of plasma HIV-1 RNA (median < 2 copies/mL, IQR
< 2-12 copies/mL, mean 8 copies/mL ± SD 12.8) compared to one
patient 8-12 weeks after IVIG treatment (median < 2 copies/mL, IQR
< 2 copies/mL, mean 1.7 copies/mL SD ± 2.3). No difference in
plasma HIV-1 RNA between treated (median < 2 copies/mL IQR < 2-
12 copies/mL, mean 8 copies/mL SD ± 12.8) and controls (median
< 2 copies/mL, IQR < 2-7.25 copies/mL, mean 5.7 copies/mL SD ±
8.9) at follow-up. Quantitative detection limit (2 copies/mL) is
marked by grid line.
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Figure 2 Correlation between plasma HIV-1 RNA and CD4+ T-
cell count. Residual plasma HIV-1 RNA correlates with CD4
+ T-cell
counts in IVIG-treated patients and controls (r = 0.46, p = 0.027).
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decreased in parallel with the cellular reservoir of HIV-1
in latently infected CD4
+ T-lymphocytes after addition
of high dosage of IVIG to effective ART. Plasma HIV-1
RNA ≥ 2 copies/mL was detected in five of seven sub-
jects at baseline, but in only one at follow-up after 8-12
weeks. These are preliminary data from a small study,
with a limited number of measurements and have to be
interpreted with caution. In the present study we did
not measure HIV-1 in resting CD4
+ T-lymphocytes.
However, our previous findings indicates that it is rea-
sonable to assume that most of the plasma HIV reser-
voir in well-treated patients originates from CD4
+
r e s t i n gc e l l s .T h i sh y p o t h e s i si sa l s os u p p o r t e db yt h e
findings of Archin et al, were the level of residual vire-
mia appears to be related to the frequency of resting
CD4
+ cell infection [11]. Therefore a measurement of
plasma HIV RNA may estimate the total plasma reser-
voir. The effects of IVIG treatment in general are com-
plex and involve modulation of expression and function
of Fc receptors, interference with complement activation
and the cytokine network. It also generates effects on
the activation and function of lymphocytes, dendritic
cells, and macrophages; and provision of anti-idiotypic
antibodies [12-14]. Therefore it is hard to speculate on
any specific and direct mechanism involved. Moreover,
it is unlikely that general immune activation results in
depletion of the latent reservoir. However, we suggest
that the effect of IVIG on resting CD4
+ T-cells is indir-
ect and that it might be mediated by cytokines and we
propose IL-7 as a possible mediator. It is known that
IL-7 can activate virus expression, and it has, in con-
junction with an anti-HIV immunotoxin, been shown to
reduce the latent reservoir in a mouse model [15]. IL-7
also seems to induce proviral reactivation from resting
T-lymphocytes isolated from HIV-1-infected patients on
ART [16]. Furthermore, transient increases in plasma
HIV-1 RNA levels and inducement of T-cell cycle entry
has been demonstrated when administrating recombi-
nant IL-7 to HIV-infected patients [17]. In this follow-
up study, we observed a rebound of HIV-1 RNA to pre-
treatment levels and no difference in plasma viral load
compared to controls in median 12.4 months after
IVIG-treatment. The transient effect on viral load might
be explained by patients not maintaining perfect adher-
ence allowing accidental viral replication to replenish
the reservoirs. It is also possible that the IVIG effect
observed in the previous study was due to a transient
effect on a cellular protein or the provirus environment.
Another explanation could be that ART, despite com-
plete adherence, does not totally reduce replication,
which is necessary to fully prevent new cells from get-
ting infected. Whether the residual viremia during ART
originates from ongoing rounds of replication is
debated. Recent studies have revealed a significant asso-
ciation between low-level viremia and baseline HIV
RNA levels, suggesting that the residual viremia is
derived from a reservoir of long-lived cells infected
before initiation of therapy [8,18]. We found no signifi-
cant correlation (p = 0.11) between residual plasma vire-
mia and levels of pre-treatment plasma HIV-1 RNA
when pooling the two groups in this study. The limited
number of subjects included in the present study might
explain these conflicting results compared to earlier stu-
dies and this study was not powered for detection of
existing possible correlation. However, we found a sig-
nificant correlation when comparing plasma HIV-1
RNA with numbers of CD4
+ T-cells and this conflicts
with earlier studies where no such correlation could be
found [18,19]. If replication does occur despite ART, it
is possible that a higher CD4
+ T-cell population may
harbour additional quantities of virus. A recent study
suggests an IL-7-mediated homeostatic proliferation of
memory CD4
+ T-cells resulting in a quantitative and
qualitative stability of the HIV reservoir [20]. The
rebound of the residual plasma viremia that we observed
in the present study may be explained by such a prolif-
eration, an event of homeostatic forces that restores the
size of the latently infected pool of resting CD4
+ T-cells.
In our previous study a consistent increase in circulating
natural Tregs was observed in all subjects after IVIG
treatment. In this follow-up study we could not detect
any significant difference in circulating natural Tregs in
IVIG-treated patients compared to controls indicating
that the increase of cells observed in the previous study
was temporary during IVIG treatment. Unfortunately,
we were not able to compare the Treg concentrations
longitudinally over time since different methods of iden-
tification of Tregs were used in the previous and present
follow-up study.
Conclusions
We could not detect a persistent effect of IVIG treatment
on the residual plasma viremia, indicating that the
decrease of the latent HIV-1 pool observed in our initial
study was transient, although not independently measured
in this study. A correlation between HIV-1 RNA and CD4
+ T-cell count was found, suggesting the possibility of a
larger pool of latently infected CD4
+ T-cells in patients
with a higher CD4
+ T-cell count. A close correlation
between the size of the latent T-cell reservoir and level of
residual plasma viral load could be expected but has not
been fully elucidated, although recently a small study
reported that levels of residual viremia were related to the
frequency of resting cell infection under suppressive treat-
ment [11]. Further studies are needed to evaluate the
immunologic effects of IVIG in HIV infection. To deter-
mine if IVIG does or does not constitute a treatment that
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cebo controlled study would be needed.
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